{"id":"W4303629005","doi":"10.3390/curroncol29100575","title":"First- and Second-Line Treatments for Patients with Advanced Hepatocellular Carcinoma in China: A Systematic Review","year":2022,"lang":"en","type":"review","venue":"Current Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Medicine; Bevacizumab; Internal medicine; Atezolizumab; Biosimilar; Oncology; Randomized controlled trial; MEDLINE; Hepatocellular carcinoma; Chemotherapy; Intensive care medicine; Cancer; Pembrolizumab; Immunotherapy","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00443163,0.001147985,0.0076033,0.007266202,0.0004956427,0.001270372,0.001490575,0.001212538,0.00340686],"category_scores_gemma":[0.01305884,0.0006126667,0.006347223,0.008790212,0.0006089828,0.001376683,0.0008212063,0.000600729,0.000182733],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002896522,"about_ca_system_score_gemma":0.01004053,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01000255,"about_ca_topic_score_gemma":0.03000656,"domain_scores_codex":[0.9968482,0.0009825446,0.001241511,0.0002470399,0.0005587213,0.0001219963],"domain_scores_gemma":[0.9911373,0.00520051,0.0023515,0.0001232206,0.001000326,0.0001872665],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.0003258668,0.00002393155,0.001742475,0.9492794,0.0121928,0.00012154,0.0001169484,0.0001033718,0.0001411934,0.0001142815,0.001325552,0.0345128],"study_design_scores_gemma":[0.001288301,0.0007198699,0.01742432,0.7521981,0.20866,0.0007743768,0.0003935157,0.0002893601,0.0003829971,0.0002811281,0.01750851,0.00007949766],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001876676,0.996995,0.00009574883,0.0001604873,0.00005686651,0.0002526045,0.000368499,0.000005923942,0.0001883233],"genre_scores_gemma":[0.02406531,0.9740816,0.0004119267,0.0004401568,0.00005668388,0.0005034148,0.0003384428,0.000002569649,0.00009988705],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.01000255,"threshold_uncertainty_score":0.02343702,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1441455491015714,"score_gpt":0.364621947691823,"score_spread":0.2204763985902516,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}